{"id":"gadoteridol-prohance","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Gadolinium retention (rare with macrocyclic agents)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gadoteridol is a macrocyclic gadolinium chelate complex that distributes into the extracellular space and increases the relaxivity of nearby water molecules, resulting in enhanced signal intensity on T1-weighted MRI images. This allows for improved visualization and characterization of tissues and lesions during MRI examinations. The macrocyclic structure provides high thermodynamic and kinetic stability, reducing the risk of gadolinium release.","oneSentence":"Gadoteridol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:15.316Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for central nervous system imaging"},{"name":"MRI contrast enhancement for body imaging including liver, kidney, and other organs"}]},"trialDetails":[{"nctId":"NCT04861077","phase":"EARLY_PHASE1","title":"Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-06","conditions":"Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT04373564","phase":"PHASE4","title":"Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","status":"RECRUITING","sponsor":"Guerbet","startDate":"2021-03-24","conditions":"Motor Function, Cognitive Function, Contrast Media","enrollment":2076},{"nctId":"NCT05915728","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology","enrollment":404},{"nctId":"NCT04879628","phase":"PHASE2","title":"Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Multiple Sclerosis","enrollment":129},{"nctId":"NCT04649034","phase":"","title":"Intraventricular Stasis In Cardiovascular Disease","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2020-11-24","conditions":"Dilated Cardiomyopathy, Thrombosis Cardiac, Stroke","enrollment":258},{"nctId":"NCT05915702","phase":"PHASE3","title":"A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-07-24","conditions":"Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology","enrollment":303},{"nctId":"NCT04248543","phase":"NA","title":"Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-12-22","conditions":"Spinal Metastases","enrollment":25},{"nctId":"NCT03396822","phase":"","title":"Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-09-24","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT05357833","phase":"EARLY_PHASE1","title":"Novel Imaging Markers in SPMS","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-06-01","conditions":"Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis","enrollment":11},{"nctId":"NCT04608812","phase":"PHASE1","title":"Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection","status":"TERMINATED","sponsor":"OncoSynergy, Inc.","startDate":"2021-03-02","conditions":"Glioma, Malignant, High Grade Glioma, Glioblastoma","enrollment":7},{"nctId":"NCT02359097","phase":"NA","title":"Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-01-06","conditions":"Glioblastoma","enrollment":29},{"nctId":"NCT03415789","phase":"","title":"Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2018-02-10","conditions":"Dilated Cardiomyopathy, Thrombosis, Stroke","enrollment":80},{"nctId":"NCT03108378","phase":"","title":"Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2014-10","conditions":"Gadolinium Retention","enrollment":28},{"nctId":"NCT03750188","phase":"","title":"Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2018-11-01","conditions":"Central Nervous System Diseases, Central Nervous System Neoplasms","enrollment":125},{"nctId":"NCT02481882","phase":"NA","title":"Baseline Cortical Haemodynamics in MS","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2017-01","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00522951","phase":"PHASE3","title":"SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Brain Metastases","enrollment":165},{"nctId":"NCT00660543","phase":"NA","title":"MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-12","conditions":"Adult Brain Glioblastoma","enrollment":14},{"nctId":"NCT01019486","phase":"PHASE4","title":"Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2009-11","conditions":"Coronary Artery Disease, Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01613417","phase":"PHASE4","title":"Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2012-08","conditions":"Brain Disease","enrollment":229},{"nctId":"NCT00709852","phase":"PHASE3","title":"Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":"Diagnostic Imaging, Central Nervous System Diseases","enrollment":402},{"nctId":"NCT00600834","phase":"","title":"Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2008-02","conditions":"Renal Insufficiency","enrollment":172}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"NEPHROGENIC SYSTEMIC FIBROSIS"},{"count":1,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":1,"reaction":"BIOPSY SKIN ABNORMAL"},{"count":1,"reaction":"COMA"},{"count":1,"reaction":"CORNEAL REFLEX DECREASED"},{"count":1,"reaction":"CSF TEST ABNORMAL"},{"count":1,"reaction":"DELAYED RECOVERY FROM ANAESTHESIA"},{"count":1,"reaction":"GAIT DISTURBANCE"},{"count":1,"reaction":"GRIP STRENGTH DECREASED"}],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gadoteridol (ProHance)","genericName":"Gadoteridol (ProHance)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gadoteridol is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including liver, kidney, and other organs.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}